Palonosetron
- Generic Name
- Palonosetron
- Brand Names
- Akynzeo, Aloxi, Palonosetron Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O
- CAS Number
- 135729-56-5
- Unique Ingredient Identifier
- 5D06587D6R
- Background
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
- Indication
For the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, as well as prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy. Also used for the prevention of postoperative nausea and vomiting for up to 24 hours post operation.
- Associated Conditions
- Nausea caused by Chemotherapy, Post Operative Nausea and Vomiting (PONV), Acute chemotherapy-induced nausea and vomiting, Delayed chemotherapy-induced nausea and vomiting
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
- Conditions
- Chemotherapy-Induced Nausea and VomitingLung Cancer
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 80
- Registration Number
- NCT02445872
- Locations
- 🇨🇳
The first affiliated hospital, Zhejiang University, Hangzhou, Zhejiang, China
Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)
- Conditions
- NauseaVomiting
- Interventions
- Radiation: Low or moderate risk radiotherapy
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2017-10-06
- Lead Sponsor
- Dr. Edward Chow
- Target Recruit Count
- 96
- Registration Number
- NCT02388750
- Locations
- 🇨🇦
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Associazione Salentina Angela Serra
- Target Recruit Count
- 134
- Registration Number
- NCT02205164
- Locations
- 🇮🇹
Ospedale Perrino, Brindisi, BR, Italy
🇮🇹A.O. Riuniti Papardo - Piemonte, Messina, ME, Italy
🇮🇹Università-Azienda Policlinico di Bari, Bari, BA, Italy
Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2016-08-24
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 642
- Registration Number
- NCT02203253
- Locations
- 🇨🇳
The First Hospital of Liaoning Medical University, Jinzhou, Liaoning, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2014-05-12
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 249
- Registration Number
- NCT02135510
- Locations
- 🇳🇱
Tergooiziekenhuizen, Hilversum, Noord Holland, Netherlands
🇳🇱Rijnstate, Arnhem, Netherlands
🇳🇱Medisch Centrum Alkmaar, Alkmaar, Noord-Holland, Netherlands
Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron
- Conditions
- Morphine Adverse Reaction
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- Kyungpook National University Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01952626
- Locations
- 🇰🇷
Kyungpook National Hospital, Daegu, Korea, Republic of
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 92
- Registration Number
- NCT01909856
- Locations
- 🇨🇳
Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery
- Conditions
- Postoperative Nausea and Vomiting
- Interventions
- First Posted Date
- 2013-04-08
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 196
- Registration Number
- NCT01825733
The Effect of Palonosetron on the QTc Interval During Perioperative Period
- Conditions
- Anesthesia, GeneralPalonosetron
- Interventions
- Drug: Normal saline
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01650961
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
- Conditions
- Malignant Neoplasm
- Interventions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2013-11-07
- Target Recruit Count
- 40
- Registration Number
- NCT01640340
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.